Niklaus H. Evitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Niklaus H. Evitt has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- James R. Swartz
Department of Chemical Engineering, Stanford University, Stanford, CA, USA
3 shared publications Jamin Koo
Department of Chemical Engineering; Stanford University; Stanford CA 94305 USA
2 shared publications- Junwei Shi
Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
2 shared publications - Rahul M. Kohli
University of Pennsylvania
2 shared publications - Russ Altman
Stanford University
2 shared publications Shamik Mascharak
A Stanford University
2 shared publications
Latest Publications
- 18 October 2021
- Published by Springer Nature in Nature Chemical Biology
- Vol. 17 (12) , 1262-1270
Controllable genome editing with split-engineered base editors
DNA deaminase enzymes play key roles in immunity and have recently been harnessed for their biotechnological applications. In base editors (BEs), the combination of DNA deaminase mutator activity with CRISPR–Cas localization confers the powerful ability to directly convert one target DNA base into another. While efforts have been made to improve targeting efficiency and precision, all BEs so far use a constitutively active DNA deaminase. The absence of regulatory control over promiscuous deaminase activity remains a major limitation to accessing the widespread potential of BEs. Here, we reveal sites that permit splitting of DNA cytosine deaminases into two inactive fragments, whose reapproximation reconstitutes activity. These findings allow for the development of split-engineered BEs (seBEs), which newly enable small-molecule control over targeted mutator activity. We show that the seBE strategy facilitates robust regulated editing with BE scaffolds containing diverse deaminases, offering a generalizable solution for temporally controlling precision genome editing.
- 18 October 2021
- Published by Springer Nature in Nature Chemical Biology
- Vol. 17 (12) , 1262-1270
Controllable genome editing with split-engineered base editors
DNA deaminase enzymes play key roles in immunity and have recently been harnessed for their biotechnological applications. In base editors (BEs), the combination of DNA deaminase mutator activity with CRISPR–Cas localization confers the powerful ability to directly convert one target DNA base into another. While efforts have been made to improve targeting efficiency and precision, all BEs so far use a constitutively active DNA deaminase. The absence of regulatory control over promiscuous deaminase activity remains a major limitation to accessing the widespread potential of BEs. Here, we reveal sites that permit splitting of DNA cytosine deaminases into two inactive fragments, whose reapproximation reconstitutes activity. These findings allow for the development of split-engineered BEs (seBEs), which newly enable small-molecule control over targeted mutator activity. We show that the seBE strategy facilitates robust regulated editing with BE scaffolds containing diverse deaminases, offering a generalizable solution for temporally controlling precision genome editing.
- Open Access
- 13 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-9
High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening
CRISPR-based genetic screening has revolutionized cancer drug target discovery, yet reliable, multiplex gene editing to reveal synergies between gene targets remains a major challenge. Here, we present a simple and robust CRISPR-Cas12a-based approach for combinatorial genetic screening in cancer cells. By engineering the CRISPR-AsCas12a system with key modifications to the Cas protein and its CRISPR RNA (crRNA), we can achieve high efficiency combinatorial genetic screening. We demonstrate the performance of our optimized AsCas12a (opAsCas12a) through double knockout screening against epigenetic regulators. This screen reveals synthetic sick interactions between Brd9&Jmjd6, Kat6a&Jmjd6, and Brpf1&Jmjd6 in leukemia cells.
- 13 July 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-9
Open AccessHigh-performance CRISPR-Cas12a genome editing for combinatorial genetic screening
CRISPR-based genetic screening has revolutionized cancer drug target discovery, yet reliable, multiplex gene editing to reveal synergies between gene targets remains a major challenge. Here, we present a simple and robust CRISPR-Cas12a-based approach for combinatorial genetic screening in cancer cells. By engineering the CRISPR-AsCas12a system with key modifications to the Cas protein and its CRISPR RNA (crRNA), we can achieve high efficiency combinatorial genetic screening. We demonstrate the performance of our optimized AsCas12a (opAsCas12a) through double knockout screening against epigenetic regulators. This screen reveals synthetic sick interactions between Brd9&Jmjd6, Kat6a&Jmjd6, and Brpf1&Jmjd6 in leukemia cells.
- 1 May 2018
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 38 (Suppl_1)
Abstract 214: Functional Analysis of the Low Density Lipoprotein Receptor Using Saturation Mutagenesis Strategies
Low density lipoprotein receptor (LDLR) genetic mutations are well-documented to cause familial hypercholesterolemia (FH) in patients. These mutations affect a broad range of LDLR functions, including LDL binding and receptor trafficking, and five classes exist to describe their functional consequences. Although over 1,000 LDLR mutants have been identified, an additional 15,000+ LDLR mutants are possible by only a single amino acid substitution in the ~160kDa protein. Since cataloging mutants would undoubtedly be of therapeutic benefit, we are systematically classifying the effect of every single amino acid substitution on LDLR function using saturation mutagenesis. LDLR was knocked out of HEK293 cells using standard CRISPR/Cas9 practices and decreased protein levels were assessed by flow cytometry and immunoblot staining. In order to introduce each individual mutation into the genomic DNA sequence for high-throughput, functional analyses, the PiggyBac transposon system was used to insert a serine-integrase attachment site into a single allele in the LDLR locus, whereby efficient knock in of LDLR mutants from a pooled cDNA library can be achieved. Mutant LDLR libraries containing ~800 single amino acid substitutions were generated using commercial oligo pools and Gibson cloning. Of particular therapeutic interest is the identification of mutations that alter LDL’s ability to bind to the receptor. In our first set of experiments, fluorescently labeled LDL was incubated with cells containing pooled single amino acid substitutions in LDLR, and cells were sorted using flow cytometry. Sorted groups ranging from fluorescent negative to positive were sent for next generation sequencing in order to identify severe vs benign mutants on receptor function. As some of these mutations may decrease LDL binding activity due to inhibited receptor trafficking, we also stained pooled cells with an antibody directed against LDLR, sorted by flow cytometry and analyzed using next generation sequencing with similar strategies. Ultimately, cataloging LDLR genetic mutations should be of great therapeutic benefit, as it will allow better diagnosis and treatment of patients suffering from FH.
- 1 May 2018
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 38 (Suppl_1)
Abstract 214: Functional Analysis of the Low Density Lipoprotein Receptor Using Saturation Mutagenesis Strategies
Low density lipoprotein receptor (LDLR) genetic mutations are well-documented to cause familial hypercholesterolemia (FH) in patients. These mutations affect a broad range of LDLR functions, including LDL binding and receptor trafficking, and five classes exist to describe their functional consequences. Although over 1,000 LDLR mutants have been identified, an additional 15,000+ LDLR mutants are possible by only a single amino acid substitution in the ~160kDa protein. Since cataloging mutants would undoubtedly be of therapeutic benefit, we are systematically classifying the effect of every single amino acid substitution on LDLR function using saturation mutagenesis. LDLR was knocked out of HEK293 cells using standard CRISPR/Cas9 practices and decreased protein levels were assessed by flow cytometry and immunoblot staining. In order to introduce each individual mutation into the genomic DNA sequence for high-throughput, functional analyses, the PiggyBac transposon system was used to insert a serine-integrase attachment site into a single allele in the LDLR locus, whereby efficient knock in of LDLR mutants from a pooled cDNA library can be achieved. Mutant LDLR libraries containing ~800 single amino acid substitutions were generated using commercial oligo pools and Gibson cloning. Of particular therapeutic interest is the identification of mutations that alter LDL’s ability to bind to the receptor. In our first set of experiments, fluorescently labeled LDL was incubated with cells containing pooled single amino acid substitutions in LDLR, and cells were sorted using flow cytometry. Sorted groups ranging from fluorescent negative to positive were sent for next generation sequencing in order to identify severe vs benign mutants on receptor function. As some of these mutations may decrease LDL binding activity due to inhibited receptor trafficking, we also stained pooled cells with an antibody directed against LDLR, sorted by flow cytometry and analyzed using next generation sequencing with similar strategies. Ultimately, cataloging LDLR genetic mutations should be of great therapeutic benefit, as it will allow better diagnosis and treatment of patients suffering from FH.
- 27 February 2018
- Published by Wolters Kluwer Health in Circulation
- Vol. 137 (9) , 975-977
Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3
- 27 February 2018
- Published by Wolters Kluwer Health in Circulation
- Vol. 137 (9) , 975-977
Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3
- 15 December 2016
- Published by Wiley in Angewandte Chemie
- Vol. 129 (4) , 1032-1036
High-Throughput Screening of Catalytic H2Production
- 15 December 2016
- Published by Wiley in Angewandte Chemie
- Vol. 129 (4) , 1032-1036
High-Throughput Screening of Catalytic H2Production
- 15 December 2016
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 56 (4) , 1012-1016
High‐Throughput Screening of Catalytic H2 Production
Hydrogenases, ferredoxins, and ferredoxin‐NADP+ reductases (FNR) are redox proteins that mediate electron metabolism in vivo, and are also potential components for biological H2 production technologies. A high‐throughput H2 production assay device (H2PAD) is presented that enables simultaneous evaluation of 96 individual H2 production reactions to identify components that improve performance. Using a CCD camera and image analysis software, H2PAD senses the chemo‐optical response of Pd/WO3 thin films to the H2 produced. H2PAD‐enabled discovery of hydrogenase and FNR mutants that enhance biological H2 production is reported. From a library of 10 080 randomly mutated Clostridium pasteurianum [FeFe] hydrogenases, we found a mutant with nearly 3‐fold higher H2 production specific activity. From a library of 400 semi‐randomly mutated Oryza sativa FNR, the top hit enabled a 60 % increase in NADPH‐driven H2 production rates. H2PAD can also facilitate elucidation of fundamental biochemical mechanisms within these systems.
- 15 December 2016
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 56 (4) , 1012-1016
High‐Throughput Screening of Catalytic H2 Production
Hydrogenases, ferredoxins, and ferredoxin‐NADP+ reductases (FNR) are redox proteins that mediate electron metabolism in vivo, and are also potential components for biological H2 production technologies. A high‐throughput H2 production assay device (H2PAD) is presented that enables simultaneous evaluation of 96 individual H2 production reactions to identify components that improve performance. Using a CCD camera and image analysis software, H2PAD senses the chemo‐optical response of Pd/WO3 thin films to the H2 produced. H2PAD‐enabled discovery of hydrogenase and FNR mutants that enhance biological H2 production is reported. From a library of 10 080 randomly mutated Clostridium pasteurianum [FeFe] hydrogenases, we found a mutant with nearly 3‐fold higher H2 production specific activity. From a library of 400 semi‐randomly mutated Oryza sativa FNR, the top hit enabled a 60 % increase in NADPH‐driven H2 production rates. H2PAD can also facilitate elucidation of fundamental biochemical mechanisms within these systems.
- 21 September 2016
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 16 (10) , W1-2
Response to Open Peer Commentaries on "Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework".
- 21 September 2016
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 16 (10) , W1-2
Response to Open Peer Commentaries on "Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework".
- Open Access
- 2 December 2015
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 15 (12) , 25-29
Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework
CRISPR germline editing therapies (CGETs) hold unprecedented potential to eradicate hereditary disorders. However, the prospect of altering the human germline has sparked a debate over the safety, efficacy, and morality of CGETs, triggering a funding moratorium by the NIH. There is an urgent need for practical paths for the evaluation of these capabilities. We propose a model regulatory framework for CGET research, clinical development, and distribution. Our model takes advantage of existing legal and regulatory institutions but adds elevated scrutiny at each stage of CGET development to accommodate the unique technical and ethical challenges posed by germline editing.
- 2 December 2015
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 15 (12) , 25-29
Open AccessHuman Germline CRISPR-Cas Modification: Toward a Regulatory Framework
CRISPR germline editing therapies (CGETs) hold unprecedented potential to eradicate hereditary disorders. However, the prospect of altering the human germline has sparked a debate over the safety, efficacy, and morality of CGETs, triggering a funding moratorium by the NIH. There is an urgent need for practical paths for the evaluation of these capabilities. We propose a model regulatory framework for CGET research, clinical development, and distribution. Our model takes advantage of existing legal and regulatory institutions but adds elevated scrutiny at each stage of CGET development to accommodate the unique technical and ethical challenges posed by germline editing.
- Open Access
- 5 June 2015
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 9 (1) , 1-8
Chemical lysis of cyanobacteria
We have developed a mixture of enzymes and chemicals that completely lyse cyanobacteria. Since the treatment involves only readily-available chemicals and simple proteins that degrade the components of the cyanobacterial cell wall, it can easily be used in high-throughput applications requiring lysis for subsequent intracellular measurements. Our lysis technique consistently enables complete lysis of several different cyanobacterial strains, and we demonstrated that DNA, mRNA, and proteins are preserved in the lysates. Chemical lysis can be superior to existing techniques because of its convenience, reliability, and amenability to a variety of downstream applications.
- 5 June 2015
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 9 (1) , 1-8
Open AccessChemical lysis of cyanobacteria
We have developed a mixture of enzymes and chemicals that completely lyse cyanobacteria. Since the treatment involves only readily-available chemicals and simple proteins that degrade the components of the cyanobacterial cell wall, it can easily be used in high-throughput applications requiring lysis for subsequent intracellular measurements. Our lysis technique consistently enables complete lysis of several different cyanobacterial strains, and we demonstrated that DNA, mRNA, and proteins are preserved in the lysates. Chemical lysis can be superior to existing techniques because of its convenience, reliability, and amenability to a variety of downstream applications.